ORNITHINE ASPARTATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H12N2O2.C4H7NO4
Molecular Weight	265.2637
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

InChIKey=IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

InChI=1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

HIDE SMILES / InChI

Molecular Formula	C4H7NO4
Molecular Weight	133.1027
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C5H12N2O2
Molecular Weight	132.161
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.hmdb.ca/metabolites/HMDB00214
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00129

Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. Ornithine is also a precursor of citrulline and arginine. Arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of arginine in tissues throughout the body. As de novo synthesis of arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to arginine).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
G-protein coupled receptor family C group 6 member A 22 Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628	Agonist 2678		112.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dietary shortage or imbalance 9 Sources: https://www.drugbank.ca/drugs/DB00129	Primary		Approved 8429	L-Ornithine Approved Use Used for nutritional supplementation, also for treating dietary shortage or imbalance.

PubMed

Title	Date	PubMed
The genome of Mycobacterium leprae: a minimal mycobacterial gene set.	2001	11532219
Diagnosis of Japanese patients with HHH syndrome by molecular genetic analysis: a common mutation, R179X.	2001	11355015
Effect of exercise on the metabolism of vitamin B6 and some PLP-dependent enzymes in young rats fed a restricted vitamin B6 diet.	2001 Apr	11508701
Effects of amino acid and trace element supplementation on pneumocandin production by Glarea lozoyensis: impact on titer, analogue levels, and the identification of new analogues of pneumocandin B(0).	2001 Apr	11464269
Agmatine deiminase from maize shoots: purification and properties.	2001 Apr	11314948
Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding.	2001 Apr	11276280
Hyperornithinemia associated with gyrate atrophy of the choroid and retina in a child with myopia.	2001 Aug	11521006
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance.	2001 Aug	11510941
Intrahepatic amino acid and glucose metabolism in a D-galactosamine-induced rat liver failure model.	2001 Aug	11481621
The potential mechanism for glutamine-induced collagen biosynthesis in cultured human skin fibroblasts.	2001 Aug	11470441
The Plasmodium falciparum bifunctional ornithine decarboxylase, S-adenosyl-L-methionine decarboxylase, enables a well balanced polyamine synthesis without domain-domain interaction.	2001 Aug 10	11390378
Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues.	2001 Aug 20	11514144
Synthesis of six novel N,N-dialkyl derivatives of spermidine and effects on growth of the fungal plant pathogen Pyrenophora avenae.	2001 Aug 21	11520618
Classical and slow-binding inhibitors of human type II arginase.	2001 Aug 7	11478904
Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats.	2001 Feb	11160605
Synthesis of a conformationally restricted substrate analogue of siderophore biosynthetases.	2001 Feb 22	11178814
Synthesis and biological activity of novel macrocyclic antifungals: acylated conjugates of the ornithine moiety of the lipopeptidolactone FR901469.	2001 Feb 26	11229752
Determination of amino acids by ion-exchange chromatography on filter paper spotted blood samples stored at different temperatures and for different periods: comparison with capillary and venous blood.	2001 Jul	11522278
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates.	2001 Jul	11491349
Abnormal elution behavior of ornitine derivatized with 1-fluoro-2,4-dinitrophenyl-5-leucinamide in advanced Marfey's method.	2001 Jul 6	11471802
The remarkable hydrophobic effect of a fatty acid side chain on the microbial growth promoting activity of a synthetic siderophore.	2001 Jun	11508848
Sustained oral lysine supplementation in ornithine delta-aminotransferase deficiency.	2001 Jun	11486915
Detection of neonatal argininosuccinate lyase deficiency by serum tandem mass spectrometry.	2001 Jun	11486903
HHH syndrome associated with callosal agenesis and disordered neuronal migration.	2001 Jun	11409836
Regulation of loblolly pine (Pinus taeda L.) arginase in developing seedling tissue during germination and post-germinative growth.	2001 Mar	11414614
In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles.	2001 Mar	11231318
Induction of arginases I and II in cornea during herpes simplex virus infection.	2001 Mar	11172921
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.	2001 Mar 6	11258880
Facilitatory and neurotoxic effects of intravitreal ornithine on the electroretinographic responses of albino rats.	2001 Mar-Apr	11244354
A new technique to elevate night time growth hormone release and a potential growth hormone feedback control loop.	2001 May	11388776
Adverse effects of excess lysine in calves.	2001 May	11374556
Expression, purification, and characterization of human type II arginase.	2001 May 1	11370664
Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.	2001 May 21	11392535
Crystallographic studies on endothelial nitric oxide synthase complexed with nitric oxide and mechanism-based inhibitors.	2001 May 8	11331003
Localization of amino acid neurotransmitters following in vitro ischemia and anoxia in the rat retina.	2001 May-Jun	11497418
Effect of L-arginine on the course of experimental colitis.	2001 Oct	11534936
SREA is involved in regulation of siderophore biosynthesis, utilization and uptake in Aspergillus nidulans.	2001 Sep	11555288
Induction of L-arginine transport is inhibited by atrial natriuretic peptide: a peptide hormone as a novel regulator of inducible nitric-oxide synthase substrate availability.	2001 Sep	11502871
Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome.	2001 Sep 11	11552031
Interstrand side chain--side chain interactions in a designed beta-hairpin: significance of both lateral and diagonal pairings.	2001 Sep 12	11535071
Allosteric control of the oligomerization of carbamoyl phosphate synthetase from Escherichia coli.	2001 Sep 18	11551199

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Measurement of Ca2+-dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of human family C G-protein-coupled receptor hGPRC6A/homologous goldfish 5.24 receptor chimeric construct (h6A/5.24) and identification of L-amino acids as agonists. The most active agonists were L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules (only L-Arg, L-Lys, and L-ornithine were able to activate h6A/5.24 at 10 uM concentration).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 21:17:47 GMT 2023` Edited by `admin` on `Fri Dec 15 21:17:47 GMT 2023`
Record UNII	JA08T3B97O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORNITHINE ASPARTATE

Common Name

English

L-ORNITHINE, L-ASPARTATE (1:1)

Common Name

English

L-ORNITHINE-L-ASPARTATE (SALT)

Common Name

English

L-ORNITHINE L-ASPARTATE

Common Name

English

ORPARAN

Brand Name

English

Ornithine aspartate [WHO-DD]

Common Name

English

L-ASPARTIC ACID, COMPD. WITH L-ORNITHINE (1:1)

Common Name

English

ORNITHINE, L-, L-ASPARTATE (1:1)

Common Name

English

ORMETA

Brand Name

English

ORNITHINE L-FORM ASPARTATE [MI]

Common Name

English

RUIGAN

Brand Name

English

ASPARTIC ACID COMPD. WITH ORNITHINE

Systematic Name

English

ASPARTIC ACID, L-, COMPD. WITH L-ORNITHINE (1:1)

Common Name

English

ORNITHINE L-FORM ASPARTATE

Common Name

English

HEPAMERZ

Brand Name

English

L-ORNITHINE-L-ASPARTATE

Common Name

English

LOLA

Common Name

English

Classification Tree Code System Code

DSLD

4334 (Number of products:33)